Tumor microenvironment (TME)-driven immune suppression in B cell malignancy

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1863, Issue 3, 2016, Pages 471-482

  Nicholas, Nicole S ^a   Apollonio, Benedetta ^a   Ramsay, Alan G ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

CLL; CTLA 4; DLBCL; Immune checkpoint blockade; Immune evasion; Lenalidomide; PD 1; PD L1; T cells

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

CANCER CELL; CHRONIC LYMPHATIC LEUKEMIA; DENDRITIC CELL; HUMAN; IMMUNE DEFICIENCY; IMMUNE EVASION; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; LARGE CELL LYMPHOMA; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; STROMA CELL; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; B LYMPHOCYTE; BIOLOGICAL MODEL; CELL COMMUNICATION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION;

B-LYMPHOCYTES; CELL COMMUNICATION; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; MODELS, IMMUNOLOGICAL; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84955209668     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2015.11.003     Document Type: Review

References (142)

1. Zenz T., et al. Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL). Best Pract. Res. Clin. Haematol. 2010, 23(1):71-84.
2. Roschewski M., Staudt L.M., Wilson W.H. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol 2014, 11(1):12-23.
3. Landau D.A., et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013, 152(4):714-726.
4. Zhang J., et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(4):1398-1403.
5. Byrd J.C., et al. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. J. Clin. Oncol. 2014, 32(27):3039-3047.
6. Pinilla-Ibarz J., Chavez J.C. Life after ibrutinib? A new unmet need in CLL. Blood 2015, 125(13):2013-2014.
7. Daver N., et al. Secondary mutations as mediators of resistance to targeted therapy in leukemia. Blood 2015, 125(21):3236-3245.
8. Klemm F., Joyce J.A. Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol. 2015, 25(4):198-213.
9. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
10. Topalian S.L., Drake C.G., Pardoll D.M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015, 27(4):450-461.
11. Lawrence M.S., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013, 499(7457):214-218.
12. Schumacher T.N., Schreiber R.D. Neoantigens in cancer immunotherapy. Science 2015, 348(6230):69-74.
13. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331(6024):1565-1570.
14. Boon T., van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996, 183(3):725-729.
15. Aguirre-Ghiso J.A. Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 2007, 7(11):834-846.
16. Chen L., Flies D.B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol. 2013, 13(4):227-242.
17. Topalian S.L., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366(26):2443-2454.
18. Schwartz R.H. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992, 71(7):1065-1068.
19. Rudd C.E., Taylor A., Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol. Rev. 2009, 229(1):12-26.
20. Ramsay A.G. Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity. Br. J. Haematol. 2013, 162(3):313-325.
21. Qureshi O.S., et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 2011, 332(6029):600-603.
22. Peggs K.S., et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009, 206(8):1717-1725.
23. Chambers C.A., et al. Secondary but not primary T cell responses are enhanced in CTLA-4-deficient CD8+ T cells. Eur. J. Immunol. 1998, 28(10):3137-3143.
24. Hodi F.S., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363(8):711-723.
25. Motta M., et al. Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia 2005, 19(10):1788-1793.
26. Ansell S.M., et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin. Cancer Res. 2009, 15(20):6446-6453.
27. Yokosuka T., et al. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med 2012, 209(6):1201-1217.
28. Keir M.E., et al. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008, 26:677-704.
29. Barber D.L., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439(7077):682-687.
30. Francisco L.M., et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009, 206(13):3015-3029.
31. Liu Y., et al. Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells. Cancer Immunol. Immunother. 2009, 58(5):687-697.
32. Liu Y., et al. B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer. Clin. Immunol. 2008, 129(3):471-481.
33. Butte M.J., et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007, 27(1):111-122.
34. Brahmer J.R., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012, 366(26):2455-2465.
35. Ansell S.M., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N. Engl. J. Med. 2015, 372(4):311-319.
36. Berger R., et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 2008, 14(10):3044-3051.
37. Armand P. Immune checkpoint blockade in hematologic malignancies. Blood 2015.
38. Armand P., et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J. Clin. Oncol. 2013, 31(33):4199-4206.
39. Burger J.A., et al. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000, 96(8):2655-2663.
40. Panayiotidis P., et al. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br. J. Haematol. 1996, 92(1):97-103.
41. Lagneaux L., et al. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 1998, 91(7):2387-2396.
42. Burger J.A., Gribben J.G. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin. Cancer Biol. 2014, 24:71-81.
43. Scott D.W., Steidl C. The classical Hodgkin lymphoma tumor microenvironment: macrophages and gene expression-based modeling. Hematol. Am. Sociol. Hematol. Educ. Prog. 2014, 2014(1):144-150.
44. Schmid C., Isaacson P.G. Proliferation centres in B-cell malignant lymphoma, lymphocytic (B-CLL): an immunophenotypic study. Histopathology 1994, 24(5):445-451.
45. Nishio M., et al. Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood 2005, 106(3):1012-1020.
46. Deaglio S., et al. CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. Blood 2005, 105(8):3042-3050.
47. Zucchetto A., et al. Monocytes/macrophages but not T lymphocytes are the major targets of the CCL3/CCL4 chemokines produced by CD38(+)CD49d(+) chronic lymphocytic leukaemia cells. Br. J. Haematol. 2010, 150(1):111-113.
48. Burger J.A., et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009, 113(13):3050-3058.
49. Kridel R., Steidl C., Gascoyne R.D. Tumor-associated macrophages in diffuse large B-cell lymphoma. Haematologica 2015, 100(2):143-145.
50. Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141(1):39-51.
51. Nunes C., et al. Expansion of a CD8(+)PD-1(+) replicative senescence phenotype in early stage CLL patients is associated with inverted CD4:CD8 ratios and disease progression. Clin. Cancer Res. 2012, 18(3):678-687.
52. Patten P.E., et al. CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. Blood 2008, 111(10):5173-5181.
53. Ghia P., et al. Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur. J. Immunol. 2002, 32(5):1403-1413.
54. Pascutti M.F., et al. IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells. Blood 2013, 122(17):3010-3019.
55. Ramsay A.G., et al. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood 2012, 120(7):1412-1421.
56. Riches J.C., et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 2013, 121(9):1612-1621.
57. Ansell S.M., et al. Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J. Clin. Oncol. 2001, 19(3):720-726.
58. Keane C., et al. CD4(+) tumor infiltrating lymphocytes are prognostic and independent of R-IPI in patients with DLBCL receiving R-CHOP chemo-immunotherapy. Am. J. Hematol. 2013, 88(4):273-276.
59. Rydstrom K., et al. CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Leuk. Lymphoma 2010, 51(9):1643-1648.
60. Chang K.C., et al. Distribution patterns of dendritic cells and T cells in diffuse large B-cell lymphomas correlate with prognoses. Clin. Cancer Res. 2007, 13(22 Pt 1):6666-6672.
61. Monti S., et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005, 105(5):1851-1861.
62. Zitvogel L., et al. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013, 39(1):74-88.
63. Coutinho R., et al. Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry: robust semi-automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOP. Haematologica 2015, 100(3):363-369.
64. Mueller S.N., Germain R.N. Stromal cell contributions to the homeostasis and functionality of the immune system. Nat. Rev. Immunol. 2009, 9(9):618-629.
65. Ruan J., et al. Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphoma. Clin. Cancer Res. 2006, 12(19):5622-5631.
66. Kurtova A.V., et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 2009, 114(20):4441-4450.
67. Lutzny G., et al. Protein kinase c-beta-dependent activation of NF-kappaB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo. Cancer Cell 2013, 23(1):77-92.
68. Ghosh A.K., et al. Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood 2010, 115(9):1755-1764.
69. Ding W., et al. Platelet-derived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. Blood 2010, 116(16):2984-2993.
70. Ding W., et al. Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression. Br. J. Haematol. 2009, 147(4):471-483.
71. Gehrke I., et al. Bone marrow stromal cell-derived vascular endothelial growth factor (VEGF) rather than chronic lymphocytic leukemia (CLL) cell-derived VEGF is essential for the apoptotic resistance of cultured CLL cells. Mol. Med. 2011, 17(7-8):619-627.
72. Paggetti J., et al. Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. Blood 2015.
73. Lenz G., et al. Stromal gene signatures in large-B-cell lymphomas. N. Engl. J. Med. 2008, 359(22):2313-2323.
74. Wada N., et al. Diffuse large B cell lymphoma with an interfollicular pattern of proliferation shows a favourable prognosis: a study of the Osaka lymphoma study group. Histopathology 2012, 60(6):924-932.
75. Marinaccio C., et al. Microvascular density, CD68 and tryptase expression in human diffuse large B-cell lymphoma. Leuk. Res. 2014, 38(11):1374-1377.
76. Badoux X., et al. Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3. Hum. Pathol. 2011, 42(12):1989-2000.
77. Suzuma K., et al. Characterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(2):721-726.
78. Cols M., et al. Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L. J. Immunol. 2012, 188(12):6071-6083.
79. Maffei R., et al. Physical contact with endothelial cells through beta1- and beta2-integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells. Haematologica 2012, 97(6):952-960.
80. Huang X., et al. Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion. J Exp Med 2010, 207(3):505-520.
81. Pedersen I.M., et al. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood 2002, 100(5):1795-1801.
82. Heinig K., et al. Access to follicular dendritic cells is a pivotal step in murine chronic lymphocytic leukemia B-cell activation and proliferation. Cancer Discov 2014, 4(12):1448-1465.
83. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 2012, 12(4):253-268.
84. Mazzoni A., et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J. Immunol. 2002, 168(2):689-695.
85. Gabrilovich D.I., et al. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J. Immunol. 2001, 166(9):5398-5406.
86. Sinha P., Clements V.K., Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J. Immunol. 2005, 174(2):636-645.
87. Liu C., et al. Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood 2007, 109(10):4336-4342.
88. Jitschin R., et al. CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. Blood 2014, 124(5):750-760.
89. Lin Y., et al. Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma. Blood 2011, 117(3):872-881.
90. Yang Z.Z., et al. Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma. Cancer Res. 2006, 66(20):10145-10152.
91. Pallasch C.P., et al. Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade. Leuk. Res. 2009, 33(3):460-464.
92. Beyer M., et al. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005, 106(6):2018-2025.
93. Kay N.E., Zarling J.M. Impaired natural killer activity in patients with chronic lymphocytic leukemia is associated with a deficiency of azurophilic cytoplasmic granules in putative NK cells. Blood 1984, 63(2):305-309.
94. Burton J.D., Weitz C.H., Kay N.E. Malignant chronic lymphocytic leukemia B cells elaborate soluble factors that down-regulate T cell and NK function. Am. J. Hematol. 1989, 30(2):61-67.
95. Katrinakis G., et al. Defective natural killer cell activity in B-cell chronic lymphocytic leukaemia is associated with impaired release of natural killer cytotoxic factor(s) but not of tumour necrosis factor-alpha. Acta Haematol. 1996, 96(1):16-23.
96. Maki G., et al. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G. Leukemia 2008, 22(5):998-1006.
97. Buechele C., et al. 4-1BB ligand modulates direct and rituximab-induced NK-cell reactivity in chronic lymphocytic leukemia. Eur. J. Immunol. 2012, 42(3):737-748.
98. Xing D., et al. Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 exvivo expansion. J. Immunother. 2010, 33(7):684-696.
99. Rimsza L.M., et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood 2004, 103(11):4251-4258.
100. Riemersma S.A., et al. Extensive genetic alterations of the HLA region, including homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune-privileged sites. Blood 2000, 96(10):3569-3577.
101. Steidl C., et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 2011, 471(7338):377-381.
102. Wilkinson S.T., et al. Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma. Blood 2012, 119(6):1459-1467.
103. Challa-Malladi M., et al. Combined genetic inactivation of beta2-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell 2011, 20(6):728-740.
104. Straus S.E., et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 2001, 98(1):194-200.
105. Stopeck A.T., et al. Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphoma. Clin. Cancer Res. 2000, 6(10):3904-3909.
106. Riches J.C., Ramsay A.G., Gribben J.G. T-cell function in chronic lymphocytic leukaemia. Semin. Cancer Biol. 2010, 20(6):431-438.
107. Dazzi F., et al. Failure of B cells of chronic lymphocytic leukemia in presenting soluble and alloantigens. Clin. Immunol. Immunopathol. 1995, 75(1):26-32.
108. Ramsay A.G., et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J. Clin. Invest. 2008, 118(7):2427-2437.
109. Ramsay A.G., et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood 2009, 114(21):4713-4720.
110. Ramsay A.G., et al. Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering rho GTPase signaling that is reversible with lenalidomide. Blood 2013, 121(14):2704-2714.
111. Kiaii S., et al. Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation. J. Clin. Oncol. 2013, 31(21):2654-2661.
112. Rosenwald A., et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003, 198(6):851-862.
113. Green M.R., et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010, 116(17):3268-3277.
114. Green M.R., et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin. Cancer Res. 2012, 18(6):1611-1618.
115. Zou W., Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol. 2008, 8(6):467-477.
116. Pasqualucci L., et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat. Genet. 2011, 43(9):830-837.
117. McClanahan F., et al. PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia. Blood 2015.
118. Andorsky D.J., et al. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin. Cancer Res. 2011, 17(13):4232-4244.
119. Curiel T.J., et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 2003, 9(5):562-567.
120. Sharma P., Allison J.P. The future of immune checkpoint therapy. Science 2015, 348(6230):56-61.
121. Tumeh P.C., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014, 515(7528):568-571.
122. Chen B.J., et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin. Cancer Res. 2013, 19(13):3462-3473.
123. Rossille D., et al. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-cell lymphoma: results from a French multicenter clinical trial. Leukemia 2014, 28(12):2367-2375.
124. Wolchok J.D., et al. Four-year survival rates for patients with metastatic melanoma who received Ipilimumab in phase II clinical trials. Ann. Oncol. 2013, 24(8):2174-2180.
125. Sagiv-Barfi I., et al. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc. Natl. Acad. Sci. U. S. A. 2015, 112(9):E966-E972.
126. Dubovsky J.A., et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 2013, 122(15):2539-2549.
127. Kater A.P., et al. How does lenalidomide target the chronic lymphocytic leukemia microenvironment?. Blood 2014, 124(14):2184-2189.
128. Kritharis A., et al. Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities. Blood 2015, 125(16):2471-2476.
129. Kronke J., et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science 2014, 343(6168):301-305.
130. Lu G., et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of ikaros proteins. Science 2014, 343(6168):305-309.
131. Gandhi A.K., et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors ikaros and aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br. J. Haematol. 2014, 164(6):811-821.
132. Fecteau J.F., et al. Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53. Blood 2014, 124(10):1637-1644.
133. Henry J.Y., et al. Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs(R) immunomodulatory compounds lenalidomide and pomalidomide. Immunology 2013, 139(3):377-385.
134. Lee B.N., et al. Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer 2011, 117(17):3999-4008.
135. Jones J.A., Byrd J.C. How will B-cell-receptor-targeted therapies change future CLL therapy?. Blood 2014, 123(10):1455-1460.
136. Maffei R., et al. Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia. Exp. Hematol. 2014, 42(2):126-136. e1.
137. Nowakowski G.S., et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study. J. Clin. Oncol. 2015, 33(3):251-257.
138. Brown E.J., Frazier W.A. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol. 2001, 11(3):130-135.
139. Jaiswal S., et al. Macrophages as mediators of tumor immunosurveillance. Trends Immunol. 2010, 31(6):212-219.
140. Majeti R., et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009, 138(2):286-299.
141. Chao M.P., et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 2010, 142(5):699-713.
142. Chao M.P., et al. Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood 2011, 118(18):4890-4901.